KR20110004462A - Ｃｍｅｔ 및 ａｘｌ 억제제, 및 ｅｒｂｂ 억제제를 사용하여 암을 치료하는 방법 - Google Patents

Ｃｍｅｔ 및 ａｘｌ 억제제, 및 ｅｒｂｂ 억제제를 사용하여 암을 치료하는 방법 Download PDF

Info

Publication number
KR20110004462A
KR20110004462A KR1020107027183A KR20107027183A KR20110004462A KR 20110004462 A KR20110004462 A KR 20110004462A KR 1020107027183 A KR1020107027183 A KR 1020107027183A KR 20107027183 A KR20107027183 A KR 20107027183A KR 20110004462 A KR20110004462 A KR 20110004462A
Authority
KR
South Korea
Prior art keywords
compound
formula
erbb
cancer
lapatinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107027183A
Other languages
English (en)
Korean (ko)
Inventor
토나 엠. 길머
제임스 지. 그레거
리 리우
홍 시
Original Assignee
글락소스미스클라인 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41257222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20110004462(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 글락소스미스클라인 엘엘씨 filed Critical 글락소스미스클라인 엘엘씨
Publication of KR20110004462A publication Critical patent/KR20110004462A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020107027183A 2008-05-05 2009-05-05 Ｃｍｅｔ 및 ａｘｌ 억제제, 및 ｅｒｂｂ 억제제를 사용하여 암을 치료하는 방법 Ceased KR20110004462A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5032208P 2008-05-05 2008-05-05
US61/050,322 2008-05-05

Publications (1)

Publication Number Publication Date
KR20110004462A true KR20110004462A (ko) 2011-01-13

Family

ID=41257222

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107027183A Ceased KR20110004462A (ko) 2008-05-05 2009-05-05 Ｃｍｅｔ 및 ａｘｌ 억제제, 및 ｅｒｂｂ 억제제를 사용하여 암을 치료하는 방법

Country Status (19)

Country Link
US (3) US20090274693A1 (https=)
EP (1) EP2274304A4 (https=)
JP (1) JP2011519941A (https=)
KR (1) KR20110004462A (https=)
CN (1) CN102083824A (https=)
AR (1) AR071631A1 (https=)
AU (1) AU2009244453B2 (https=)
BR (1) BRPI0912582A2 (https=)
CA (1) CA2723699A1 (https=)
CL (1) CL2009001063A1 (https=)
EA (1) EA020779B1 (https=)
IL (1) IL209057A0 (https=)
MX (1) MX2010012101A (https=)
PE (1) PE20091832A1 (https=)
SG (1) SG190623A1 (https=)
TW (1) TW201006829A (https=)
UY (1) UY31800A (https=)
WO (1) WO2009137429A1 (https=)
ZA (1) ZA201007722B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10000569B2 (en) 2014-05-09 2018-06-19 Samsung Electronics Co., Ltd. Anti-cMet/anti-EGFR/anti-HER3 multispecific antibodies and use thereof

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
MA33208B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
PT2451445T (pt) 2009-07-06 2019-07-10 Boehringer Ingelheim Int Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
TW201106972A (en) * 2009-07-27 2011-03-01 Genentech Inc Combination treatments
WO2011014872A2 (en) * 2009-07-31 2011-02-03 The Johns Hopkins University Compositions and methods for diagnosing, treating or preventing neoplasias
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2896632B1 (en) * 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
EA030435B1 (ru) 2010-07-16 2018-08-31 Экселиксис, Инк. ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
MX352926B (es) 2010-09-27 2017-12-14 Exelixis Inc Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
SG191230A1 (en) * 2010-12-23 2013-07-31 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
CN102532109B (zh) * 2010-12-27 2015-05-13 浙江海正药业股份有限公司 一种拉帕替尼及其盐的合成方法
CN102093421B (zh) * 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
MX2013012695A (es) * 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
EP2758057B1 (en) 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis
CN104395284A (zh) 2011-10-20 2015-03-04 埃克塞里艾克西斯公司 制备喹啉衍生物的方法
SG11201402004YA (en) * 2011-11-14 2014-05-29 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
EP3590538A1 (en) * 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
DK2810937T3 (en) 2012-01-31 2017-03-13 Daiichi Sankyo Co Ltd PYRIDONE DERIVATIVES
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103664879A (zh) * 2012-09-17 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103705521A (zh) * 2012-09-28 2014-04-09 韩冰 一类治疗脑梗塞的化合物及其用途
WO2014093750A1 (en) * 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment
CA2907334C (en) 2013-03-15 2021-12-07 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
BR112016008125B1 (pt) 2013-10-14 2023-11-21 Janssen Biotech, Inc. Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
US11045468B2 (en) 2014-02-04 2021-06-29 Astellas Pharma Inc. Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EP3119476A1 (en) 2014-03-17 2017-01-25 Exelixis, Inc. Dosing of cabozantinib formulations
EP3125935B1 (en) 2014-04-03 2019-10-23 Merck Patent GmbH Combinations of cancer therapeutics
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
MX382904B (es) 2014-08-05 2025-03-13 Exelixis Inc Combinaciones de fármacos para tratar mieloma múltiple.
ES2749726T3 (es) 2014-12-25 2020-03-23 Ono Pharmaceutical Co Derivado de quinolina
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
MA45412A (fr) 2016-06-21 2021-05-26 Janssen Biotech Inc Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine
CN107235896B (zh) * 2016-09-13 2019-11-05 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
CN107235897B (zh) * 2016-09-27 2019-08-16 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
CN110225770B (zh) 2016-12-14 2022-04-26 杨森生物科技公司 结合cd8a的纤连蛋白iii型结构域
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
TWI779007B (zh) 2017-01-26 2022-10-01 日商小野藥品工業股份有限公司 喹啉衍生物的乙磺酸鹽
WO2018151177A1 (ja) 2017-02-15 2018-08-23 大鵬薬品工業株式会社 医薬組成物
JP7074760B2 (ja) 2017-09-08 2022-05-24 大鵬薬品工業株式会社 抗腫瘍剤及び抗腫瘍効果増強剤
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
BR112021014504A2 (pt) * 2019-01-25 2021-09-28 Exelixis, Inc. Compostos para o tratamento de transtornos dependentes de cinase
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
CN115073367A (zh) * 2021-03-16 2022-09-20 南京科默生物医药有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
EP4323008A4 (en) 2021-04-14 2026-02-25 Aro Biotherapeutics Company FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
WO2024163400A1 (en) 2023-01-31 2024-08-08 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
ITRM20030475A1 (it) * 2003-10-15 2005-04-16 Sipa Societa Industrializzazione P Rogettazione E Impianto e metodo per il condizionamento termico di oggetti
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
EP1962903B1 (en) * 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
US20080058312A1 (en) * 2006-01-11 2008-03-06 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
PL2101759T3 (pl) * 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
AU2008239594B2 (en) * 2007-04-13 2013-10-24 Beth Israel Deaconess Medical Center Methods for treating cancer resistant to ErbB therapeutics
KR101523788B1 (ko) * 2007-05-17 2015-06-26 제넨테크, 인크. 뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
HRP20160625T1 (hr) * 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10000569B2 (en) 2014-05-09 2018-06-19 Samsung Electronics Co., Ltd. Anti-cMet/anti-EGFR/anti-HER3 multispecific antibodies and use thereof

Also Published As

Publication number Publication date
CN102083824A (zh) 2011-06-01
AU2009244453B2 (en) 2012-07-19
EA020779B1 (ru) 2015-01-30
US20090274693A1 (en) 2009-11-05
CA2723699A1 (en) 2009-11-12
JP2011519941A (ja) 2011-07-14
US20130150363A1 (en) 2013-06-13
UY31800A (es) 2009-11-10
AR071631A1 (es) 2010-06-30
AU2009244453A1 (en) 2009-11-12
SG190623A1 (en) 2013-06-28
CL2009001063A1 (es) 2010-09-24
IL209057A0 (en) 2011-01-31
MX2010012101A (es) 2010-11-30
EP2274304A1 (en) 2011-01-19
ZA201007722B (en) 2011-08-31
US20130142790A1 (en) 2013-06-06
PE20091832A1 (es) 2009-12-25
EA201071268A1 (ru) 2011-06-30
TW201006829A (en) 2010-02-16
BRPI0912582A2 (pt) 2015-07-28
WO2009137429A1 (en) 2009-11-12
EP2274304A4 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
AU2009244453B2 (en) Method of treating cancer using a cMET and AXL inhibitor and an erbB inhibitor
CN112955137B (zh) 组合疗法
RU2601892C2 (ru) Комбинированная терапия антагонистами с-мет и egfr
KR20240014585A (ko) 악성 종양 치료용 제제 및 조성물
US10011659B2 (en) Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
JP2022027658A (ja) チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物
TW202002984A (zh) 用於組合療法之抗癌症醫藥組成物
CN112423745A (zh) 波齐替尼与抗-her1抗体、抗-her2抗体或抗-her4抗体的组合物及其使用方法
TW202019412A (zh) 波齊替尼(poziotinib)與細胞毒性劑及／或其他分子靶向劑之組合及其用途
EP3176183A1 (en) Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
US20140056910A1 (en) Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug
WO2022107864A1 (ja) 縮合ピリミジン化合物を有効成分とする脳移行性腫瘍治療剤
CN118434422A (zh) 抗体-药物缀合物和rasg12c抑制剂的组合
TW202532073A (zh) 以N-(4-(4-胺基-6-乙炔基-5-(喹啉-3-基)-7H-吡咯并[2, 3-d]嘧啶-7-基)雙環[2. 2. 1]庚烷-1-基)-5-甲基吡-2-甲醯胺或其鹽為有效成分之腦移行性腫瘤治療劑
EP4724151A1 (en) A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
HK40044450A (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
HK40054690A (en) Combination of antibody-drug conjugate and kinase inhibitor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101203

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140502

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151014

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160205

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151014

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I